Novo Nordisk slides on pressure from Lilly’s pill study

The triumph of Ozempic, Wegovy, and related drugs, including Lilly’s Zepbound, has set off a push toward the next frontier: a pill that’s easier to take and less expensive to make. The Lilly study exacerbates the pressure on Novo, whose market value has dropped by a third since the start of the year.

Source